

**LETTER OF ANNOUNCEMENT**  
**EMVO notice of the new Participation Agreement**

Thursday, the 27<sup>th</sup> of September 2018

Dear (Future) On-boarding Partner,

EMVO would like to announce that a new Participation Agreement (PA) is being prepared. The purpose of the new PA is to cover your participation in the full scale operational mode of the European Medicines Verification System (EMVS) (Operational Phase) and govern the conditions for the grant of rights that are necessary for the transmission of OBP data to National Systems through the European Hub.

The Operational Phase follows the Implementation Phase of the EMVS and starts on the 9<sup>th</sup> of February 2019, at 00:00 CET. Therefore, the new Participation Agreement will soon be finalised and distributed to all On-boarding Partners (OBPs) in November 2018 approximately.

To facilitate the administration process and as foreseen in the new PA, no hard copy will be required from the OBP to be sent to EMVO. The OBP will be requested to upload a signed PA via its account on the OBP Portal and EMVO will exchange in the same way its scanned copy. In case a change in the OBP's Authorized Representative\* has occurred between execution of the current and new PA, the OBP will be requested to provide EMVO with sufficient proof thereto by uploading such proof on the OBP Portal along with the copy of the signed PA.

In the event of any question or uncertainty, please do not hesitate to contact our Helpdesk:

Tel. Helpdesk: +372 611 90 44

E-Mail: [helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

**EMVO Team**

**European Medicines Verification Organisation**

[www.emvo-medicines.eu](http://www.emvo-medicines.eu)

[helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

\* OBP's Authorised Representative is (are) the person(s) who is (are) authorised to sign on behalf of and engage the company, e.g. the person who signed the PA for the Implementation Phase.